Researchers from Sichuan University report recent findings in head and neck cancer
2009 AUG 3 - (NewsRx.com) -- "Ataxia-telangiectasia-mutated (ATM) is a radiosensitization gene. In the present study, we investigated the efficacy of poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles containing ATM antisense oligonucleotides (ASOs) for the radiosensitization of head and neck squamous-cell carcinoma in mice, using the SCCVII cell line," researchers in Chengdu, People's Republic of China report. "Nanoparticles containing ATM ASOs were prepared with PLGA by using a double-emulsion solvent evaporation method. The results showed that the nanoparticles were suitable for intracellular uptake, and ATM ASOs inhibited ATM expression when delivered by using nanoparticles or lipofectin, but not in their free form. Meanwhile, we found that ATM reduction sensitized SCCVII cells in vitro and tumors in vivo to irradiation," wrote J. Zou and colleagues, Sichuan University. The researchers concluded: "Biodegradable PLGA nanoparticles, used as a delivery carrier, enhanced intracellular uptake of ATM ASOs into SCCVII cells and the inhibitory effect of ATM ASOs. These results demonstrated that antisense ATM therapy, using PLGA nanoparticles, might provide a therapeutic benefit to patients undergoing radiation therapy for head and neck squamous-cell carcinoma.." Zou and colleagues published their study in Cancer Biotherapy and Radiopharmaceuticals (Inhibition of Ataxia-Telangiectasia Mutated by Antisense Oligonucleotide Nanoparticles Induces Radiosensitization of Head and Neck Squamous-Cell Carcinoma in Mice. Cancer Biotherapy and Radiopharmaceuticals, 2009;24(3):339-346). For additional information, contact S.X. Liu, Sichuan University, W China Hospital, Dept. of Otolaryngology, 37 Guo Xue Rd., Chengdu 610041, People's Republic of China. Publisher contact information for the journal Cancer Biotherapy and Radiopharmaceuticals is: Mary Ann Liebert Inc., 140 Huguenot Street, 3RD FL, New Rochelle, NY 10801, USA. Keywords: People's Republic of China, Chengdu, Antisense Technology, Ataxia-telangiectasia, Biotechnology, Dermatology, Gene Therapy, Genetics, Head and Neck Cancer, Head and Neck Carcinoma, Neurology, Oncology, Pharmaceuticals, Squamous Cell Carcinoma, Telangiectasia, Treatment, Sichuan University. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2009, Clinical Oncology Week via NewsRx.com.
|
